Equillium to Present at 2020 RBC Capital Markets Virtual Global Healthcare Conference
07 mai 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Fluidigm Announces First Quarter 2020 Financial Results
07 mai 2020 16h05 HE
|
Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...
aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results
06 mai 2020 08h03 HE
|
aTyr Pharma, Inc.
SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Announces Publication of Two Abstracts in American Journal of Respiratory and Critical Care Medicine
05 mai 2020 08h03 HE
|
aTyr Pharma, Inc.
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference Findings confirm that aTyr’s lead clinical candidate, ATYR1923, selectively binds...
Hebrew University to Collaborate with Cytovia Therapeutics
18 mars 2020 09h00 HE
|
Cytovia Therapeutics
NEW YORK and JERUSALEM, March 18, 2020 (GLOBE NEWSWIRE) -- Yissum, the technology transfer company of The Hebrew University of Jerusalem and Cytovia Therapeutics, Inc, a biopharmaceutical company...
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
13 févr. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
10 févr. 2020 16h05 HE
|
Fluidigm Corporation
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates...
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
29 janv. 2020 16h07 HE
|
Equillium
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Cancer Advances, Inc. Announces Poster Presentation at ASCO GI
21 janv. 2020 22h20 HE
|
Cancer Advances Inc
DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...
I-MAB Announces Pricing of U.S. Initial Public Offering
17 janv. 2020 00h36 HE
|
I-Mab
SHANGHAI, China and ROCKVILLE, Md., Jan. 17, 2020 (GLOBE NEWSWIRE) -- I-Mab (“I-Mab” or the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery,...